COMMENTARY Open Access

Strategy drives implementation: COVID vaccination in Israel



Sherry Glied

Abstract

This commentary on Rosen, Waitzberg, and Israeli's assessment of Israel's COVID response points to differences in the coherence of each national government's strategy as the key factor influencing the effectiveness of the vaccine drive. The strengths of the Israeli healthcare system facilitated implementation of the roll-out, but the government's unambiguous prioritization of vaccination drove implementation success.

Keywords: COVID-19, Comparative health systems, United States government

Main text

In ordinary times, the Israeli healthcare system, with its low costs, excellent outcomes, and high levels of consumer satisfaction functions quite effectively. In its roll-out of COVID-19 vaccination, it is unambiguously the global leader.

Bruce Rosen, Ruth Waitzberg, and Avi Israeli have laid out a broad set of features of the Israeli rollout that have led to its success [1]. These include Israel's centralized structure (which eliminated the need to coordinate with sub-national governments) and its small size (which made procuring vaccine for the entire population more feasible). I want to focus on one broad key difference between the Israeli and US experiences that has shaped the differences in trajectories. The Israeli government, however fractionated on other issues, was unified in approaching COVID vaccination as a crucial, urgent response to a nation-threatening emergency. The US Federal government had no such unified vision. It is certainly true that the Israeli healthcare system was well organized to support the government's strategy. The disappointing experience to date in the US, however, has more to do with the lack of such an overarching strategy than with the any of the many weaknesses of the healthcare system itself.

Israel's view of COVID vaccination as mission critical gave the government latitude to make large-scale vaccine procurement deals with Pfizer (and later Moderna) without worrying too much about the pricing or data-sharing arrangements in the deal. The government sensibly recognized that the ongoing costs, both economic and social, of the continuing pandemic were so great that any vaccine overpayment would quickly be recouped through economic growth – and would surely be forgiven by the public. The ongoing involvement of internal security agencies in Israeli contact tracing efforts (unthinkable in the US) likely muted any concerns about any sharing of aggregated data with drug companies.

The sense of urgency extended into the rollout. While authorities in the US agonized over the ethical implications of the vaccine prioritization list, settling on a set of parameters far too complicated for implementation and then nearly immediately readjusting them, Israel proceeded with a straightforward, age-based criterion. Consistent with a sense of social solidarity around the effort, infractions of the priority rules (vaccination of adult children bringing elderly parents to vaccination sites, for example) were treated as understandable and forgivable. In the US, similar slips, mainly associated with the need to

This comment refers to the article available at https://doi.org/10.1186/s13584-021-00440-6.

Correspondence: sherry.glied@nyu.edu

Robert F. Wagner Graduate School of Public Service, New York University, New York USA



© The Author(s). 2021 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

use up open vials of vaccine, generated disproportionate recriminations. The sanguine attitude in Israel was certainly helped by the sense that the timetable for complete national vaccination was short and that line-jumpers were not gaining much of an advantage.

The final piece of the strategy was the experience and salience for the Israeli healthcare system and society of responding to national emergencies. While pandemic preparation has been a staple of local government planning and JCAHO accreditation in the US, and was taken very seriously in the years immediately following 9/11, the exercise had become more perfunctory as emergencies seemed farther away. The Israeli systems never had the luxury of such complacency.

Israel's ability to quickly roll out its COVID strategy is testimony to the strength and resilience of its healthcare system. But it's difficult to draw broader lessons from it, as the situation is unprecedented and, we hope, unlikely to be repeated. The more general lesson, however, is the importance of a unified strategy in recognizing and responding to a national emergency. Let's hope that the incoming Biden administration sees Israel's experience as an exemplar of that lesson.

Acknowledgements

I thank Bruce Rosen for useful conversations in preparation of this article.

Author's contributions

Sherry Glied wrote this paper. The author(s) read and approved the final manuscript.

Funding

None.

Availability of data and materials

Not applicable

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

Not applicable.

Received: 17 January 2021 Accepted: 26 January 2021 Published online: 01 February 2021

Reference

 Rosen B, Waitzberg R, Israeli A. Israel's rapid rollout of vaccinations for COVID-19. Isr J Health Policy Res. 2021;10:6. https://doi.org/10.1186/s13584-021-00440-6.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

